Tag Archives: corticobasal degeneration

Seeing the Data with New Eyes

The data suggest that it is time to redefine the clinical diagnosis of corticobasal degeneration

Corticobasal degeneration (CBD) is a progressive neurological disorder first described in 1968 by Rebeiz, Richardson and Kolodny. Yet, only recently has there been a systematic effort to reliably diagnose this condition. Nothing can be more discouraging than to have a loved one misdiagnosed during life. Furthermore, it is now known that CBD is caused by abnormal accumulations of the protein tau and, as disease-specific therapies are emerging, getting the right diagnosis has become critically important. Read more

Consortium to Study Tauopathies: Finding novel solutions through collaboration

One year ago, a consortium of just over 20 international clinician-scientists came together to understand, and ultimately treat and cure, tau-related disorders (tauopathies) including progressive supranuclear palsy (PSP), frontotemporal dementia with parkinsonism (FTD-P) and corticobasal degeneration (CBD). Read more

Seeing is Understanding

How autopsy teaches us and guides the search for a cure

In many cases, autopsy results help a patient’s family by confirming or refuting the clinical diagnosis. But autopsy also benefits the community through medical research. By observing the changes in a brain caused by disease, a pathologist can correlate tissue changes with clinical data, validate new clinical diagnostic technology, monitor the effectiveness of new drug therapies and suggest possible new types of treatments.

Participants in the UCSF Memory and Aging Center’s Autopsy Program have contributed to improving the diagnosis of dementia. For example, corticobasal degeneration, progressive supranuclear palsy and frontotemporal dementia with motor neuron disease are separate disorders that share a wide variety of overlapping symptoms. A team lead by Dr. Bruce Miller was able to correlate unique initial symptoms with the pathologically confirmed diagnoses to improve early diagnosis, which is when treatments would be the most successful for the patient. This study was only possible because each clinical diagnosis had been confirmed through autopsy. Dr. Michael Rosenbloom presented the results at the Annual Meeting of the American Academy of Neurology.